EPO and small cell lung carcinoma: This multicentre study was designed to evaluate the efficacy and safety of epoetin α in preventing the decline in haemoglobin (Hb) level, and to determine whether the transfusion requirement could be reduced, in patients receiving 4–6 cycles of primarily platinum-based combination cyclic chemotherapy for small cell lung cancer (SCLC).